NCT06562738 Clinical Study on Efficacy and Safety of Hetrombopag in the Preoperative Patients of Thrombocytopenia
| NCT ID | NCT06562738 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | The Third People's Hospital of Chengdu |
| Condition | Thrombocytopenia |
| Study Type | INTERVENTIONAL |
| Enrollment | 55 participants |
| Start Date | 2024-06-01 |
| Primary Completion | 2025-01-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 55 participants in total. It began in 2024-06-01 with a primary completion date of 2025-01-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is an investigator-initiated, single-arm, prospective clinical study to evaluate the efficacy and safety of heptapopal in the treatment of thrombocytopenia prior to elective surgery
Eligibility Criteria
Inclusion Criteria: 1. Age ≥18 years old; diagnosis of immune thrombocytopenia. 2. Platelets ≤75×10\^9/L before scheduled elective surgery. Exclusion Criteria: 1. History of allergy to Thrombopoietin Receptor Agonists (TPO-RA) drugs; 2. Severe bleeding symptoms, such as gastrointestinal bleeding, bleeding of important organs, and intracranial bleeding; 3. Thrombotic diseases, such as pulmonary embolism, arterial thrombosis and disseminated intravascular coagulation (DIC); 4. Positive anti-human immunodeficiency virus antibody or anti-treponema pallidum specific antibody; 5. New York Heart Association (NYHA) Grade 3 or 4 congestive heart failure; 6. History of angina pectoris, myocardial infarction or cerebral infarction within 6 months before the screening period; 7. Have an active infection that is difficult to control; 8. Pregnant or lactating women; 9. Other conditions determined by the investigator to be unsuitable for inclusion in the study
Contact & Investigator
JING TAN, MD
PRINCIPAL INVESTIGATOR
成都市第三人民医院
Frequently Asked Questions
Who can join the NCT06562738 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Thrombocytopenia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06562738 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06562738 currently recruiting?
Yes, NCT06562738 is actively recruiting participants. Contact the research team at 79468064@qq.com for enrollment information.
Where is the NCT06562738 trial being conducted?
This trial is being conducted at Chengdu, China.
Who is sponsoring the NCT06562738 clinical trial?
NCT06562738 is sponsored by The Third People's Hospital of Chengdu. The principal investigator is JING TAN, MD at 成都市第三人民医院. The trial plans to enroll 55 participants.